Full-Time

Senior Software Engineer

Multiple Teams

Posted on 8/21/2025

Pattern Bioscience

Pattern Bioscience

51-200 employees

AI-driven rapid bacterial ID and AST

No salary listed

Lehi, UT, USA

Hybrid

Hybrid position.

Category
Software Engineering (2)
,
Requirements
  • Strong experience building production software (typically 3–5+ years)
  • Ability to quickly learn creative tools and workflows to better serve end users
  • Comfort working across the stack, from backend APIs to front-end interfaces
  • Curiosity and discernment in applying AI to real-world creative challenges
  • A collaborative mindset with strong communication skills for cross-disciplinary work
Responsibilities
  • Collaborate directly with creative teams to deeply understand their processes and needs
  • Design and deliver tools that streamline workflows and open new creative possibilities
  • Integrate AI thoughtfully into creative pipelines—enhancing, not replacing, human creativity
  • Iterate quickly with direct feedback from end users. Build systems with strong architecture, testing, and observability

Pattern Bioscience develops rapid clinical diagnostics that identify bacterial infections and determine antibiotic resistance. Its system uses single-cell analysis with AI pattern recognition to deliver definitive ID/AST results in about four hours. The product suite includes diagnostic devices, consumables, service contracts, and software for AI analysis. By speeding and improving accuracy, Pattern Bioscience aims to help hospitals reduce inappropriate antibiotic use and combat antibiotic resistance.

Company Size

51-200

Company Stage

Series D

Total Funding

$91.6M

Headquarters

Austin, Texas

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • $43M Series D funding from AMR Action Fund supports FDA 510(k) submission.
  • $40.9M BARDA contract accelerates pneumonia and bacteremia panel development.
  • Over 1,000 samples enrolled in multi-center trial for Q3 regulatory push.

What critics are saying

  • Accelerate Diagnostics' PhenoVue captures market with FDA-cleared 3-hour AST.
  • BioFire's FilmArray dominates ICU syndromic testing, sidelining single-pathogen focus.
  • Clinical trial failure by mid-2026 exhausts Series D runway, halting launch.

What makes Pattern Bioscience unique

  • Digital CultureTM enables culture-free phenotypic ID/AST in four hours.
  • Single-cell analysis captures all resistance mechanisms unlike genotypic tests.
  • Pneumonia ID/AST Panel targets critically ill patients with FDA Breakthrough Designation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

Paid Holidays

401(k) Company Match

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

-1%
Legal Desire
Nov 19th, 2025
Pattern Bioscience Raises $43M Series D

Pattern Bioscience has raised $43 million in Series D funding, led by AMR Action Fund, Illumina Ventures, and Omnimed Capital. The funds will support a US multi-center clinical trial and regulatory submission for their Pneumonia ID/AST Panel, which has FDA Breakthrough Device Designation and is backed by a BARDA contract worth up to $40.9 million. Latham & Watkins LLP represented Pattern Bioscience in the transaction.

VCBay
Apr 29th, 2023
Austin-based Biotech startup Pattern Bioscience raises USD 28.7 million in Series C funding

To quickly develop effective treatments for drug-resistant bacterial infections, Pattern is a leader in the application of single-cell microbiology.

Business Wire
Apr 28th, 2023
Pattern Bioscience Secures $28.7 Million in Series C Financing

Pattern Bioscience secures $28.7 million in Series C financing to accelerate development of first-of-its-kind infectious disease diagnostic platform

FinSMEs
Apr 27th, 2023
Pattern Bioscience Raises $28.7M in Series C Financing

Pattern Bioscience, an Austin, TX-based company which specializes in rapid diagnosis and antibiotic susceptibility testing (AST) for bacterial infections, raised $28.7M in Series C funding.

360Dx
Apr 27th, 2023
Pattern Bioscience Closes $28.7M Series C Financing Round | 360Dx

Including the Series C round, Pattern has now raised $68 million to date, the company said in a statement.

INACTIVE